Clinical Trials Browser

HER2-positive Early Breast Cancer

Breast Neoplasms, Inflammatory Breast Neoplasms

Breast Neoplasms, Patient Preference, Inflammatory Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

HER2-positive Metastatic Breast Cancer

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Locally Advanced Breast Cancer

Breast Neoplasms

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Neoplasm Metastasis

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Her2-Positive Breast Cancer

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

HER2-positive Breast Cancer

HER2-positive Breast Cancer

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Neoplasm Metastasis

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Clinical Trials

A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer

Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer

ProHer

Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

APHINITY

Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer

MARGOT

Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer

Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer

Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC

T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA

TOUCH

IMpassion050

FeDeriCa

A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)

Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer

PEONY

Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer

Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy

1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.

Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.

PUFFIN

A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy

Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy

Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer

PERTAIN

PERUSE

Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer

Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer

Safety Study of Pertuzumab (in Combination With Trastuzumab and Docetaxel) in Indian Participants With Breast Cancer

Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer

Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer

SAPPHIRE

A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)

STEFNE

Neohttp

A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.

A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Participants With Advanced Breast Cancer

A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer

VELVET

A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) in Participants With Metastatic Breast Cancer

A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer

Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer

A Study of Pertuzumab in Participants With Metastatic Breast Cancer

A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab

Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression